Pirfenidone Tablet, Coated
Product Images NDC 71335-2944

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Pirfenidone (NDC 71335-2944). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352944)

Label for Pirfenidone Tablets, 267 mg coated tablets, oral use. The label shows an NDC number 71335-2944-1 with a package quantity of 270 tablets (3 bottles of 90 tablets each). It indicates the product is relabeled by Bryant Ranch Prepack, Inc. and manufactured by Alembic Pharmaceuticals Limited. Storage instructions recommend keeping at controlled room temperature.*

FDA Label Image

Figure 1 (Pirfenidone Figure1)

A cumulative distribution plot comparing percent of patients by absolute change in %FVC from baseline to week 52 between Pirfenidone and placebo groups. The x-axis shows absolute change in %FVC, ranging from -30% to +10%. The y-axis shows percent of patients, from 0% to 100%. Two lines represent Pirfenidone (solid) and placebo (dotted), illustrating differences in %FVC decline or no decline over time.*

FDA Label Image

Figure 2 (Pirfenidone Figure2)

A line graph showing mean change in forced vital capacity (FVC) in mL over 52 weeks comparing Pirfenidone and placebo groups. The x-axis represents weeks from 0 to 52, and the y-axis shows the mean change in FVC from 0 to -500 mL. Two lines are plotted: a solid line with square markers for Pirfenidone (n=278) showing less decline, and a dashed line with triangle markers for placebo (n=277) showing a greater decline over time.*

FDA Label Image

Figure 3 (Pirfenidone Figure3)

A survival curve graph comparing the percentage of patients alive over time in weeks for Pirfenidone versus Placebo groups. The x-axis represents time in weeks up to 120, and the y-axis shows the percentage of patients alive from 0 to 100%. The solid line represents Pirfenidone (n=623) and the dotted line represents Placebo (n=624). A hazard ratio with 95% confidence interval is also displayed. Patient counts at risk are listed below the x-axis.*

FDA Label Image

Pirfenidone-pi-table1 (Pirfenidone Pi Table 1)

A dosing schedule table for Pirfenidone Tablets 267 mg showing the number of tablets to be taken each morning, afternoon, and evening over three time periods: days 1-7 (1 tablet each time, total 3 per day), days 8-14 (2 tablets each time, total 6 per day), and days 15 onward (3 tablets each time, total 9 per day).*

FDA Label Image

Pirfenidone-pi-table-2 (Pirfenidone Pi Table 2)

A dosing schedule table for Pirfenidone Tablets 801 mg showing daily pill intake divided into three time periods: morning (breakfast), afternoon (lunch), and evening (dinner). From day 15 onward, it prescribes one pill at each time, totaling three pills per day.*

FDA Label Image

Pirfenidone (Pirfenidone Structure)

Chemical structure of pirfenidone showing a pyridinone ring attached to a phenyl group with specific methyl substitution.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.